{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T16:01:50Z","timestamp":1795276910889,"version":"4.10.3"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>The broader application of immune checkpoint inhibitors (ICIs) has led to increased recognition of rare but clinically significant adverse effects (AEs), including small bowel obstruction (SBO). This case aims to elucidate the clinical features and management challenges of ICI-associated SBO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>The first case involves a 67-year-old male patient with esophageal malignancy who was hospitalized due to painful abdominal distension following the 2 cycles administration of tislelizumab in conjunction with nab-paclitaxel. The second case concerns a 59-year-old male patient with pancreatic malignancy who developed abdominal pain and distension after undergoing combination capecitabine with sintilimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Imaging confirmed incomplete SBO in the first patient, while the second showed SBO with abdominal effusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>In consideration of the AEs associated with ICI therapy, the patient was treated with glucocorticoids. Initial management included fasting, and administration of cefoperazone\u2013sulbactam for anti-infection therapy along with methylprednisolone. Another patient underwent catheter placement and received octreotide treatment, but the therapeutic response was unsatisfactory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient 1 symptoms gradually improved. However, despite therapy, the patient 2\u2019s SBO did not improve, and he was subsequently transferred to the hospital for further management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>With expanding use of ICIs, immune-related AEs have emerged. Clinicians should remain highly vigilant for gastrointestinal symptoms in patients receiving ICIs, as early recognition of SBO is crucial for timely diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044910","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:05:45Z","timestamp":1759781145000},"page":"e44910","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Small bowel obstruction in patients associated with immune checkpoint inhibitors combined with chemotherapy: Two case reports and a review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6327-7476","authenticated-orcid":false,"given":"Xuefen","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huzhou Nanxun People\u2019s Hospital, Huzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huzhou Nanxun People\u2019s Hospital, Huzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huzhou Nanxun People\u2019s Hospital, Huzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3644-9518","authenticated-orcid":false,"given":"Qihao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Center, Department of Medical Oncology, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijscr.2020.12.096","article-title":"Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction \u2013 a case report.","volume":"79","author":"Mourad","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"e000453","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.","volume":"8","author":"Desai","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10140-019-01731-x","article-title":"Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy.","volume":"27","author":"Tso","year":"2020","journal-title":"Emerg Radiol"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1078155217738325","article-title":"Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.","volume":"25","author":"Fragulidis","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-0041-1725204","article-title":"Small bowel obstruction.","volume":"34","author":"Aka","year":"2021","journal-title":"Clin Colon Rectal Surg"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11894-017-0566-9","article-title":"A systematic review of the clinical presentation, diagnosis, and treatment of small bowel obstruction.","volume":"19","author":"Rami Reddy","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jso.25451","article-title":"Malignant bowel obstruction.","volume":"120","author":"Krouse","year":"2019","journal-title":"J Surg Oncol"},{"key":"R8-20260526","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/15360288.2022.2106012","article-title":"Comprehensive diagnosis and management of malignant bowel obstruction: a review.","volume":"37","author":"Demarest","year":"2023","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1097\/JS9.0000000000001393","article-title":"Pharmacologic prevention and therapy of postoperative paralytic ileus after gastrointestinal cancer surgery: systematic review and meta-analysis.","volume":"110","author":"Reichert","year":"2024","journal-title":"Int J Surg"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCG.0000000000001047","article-title":"Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction.","volume":"52","author":"Downes","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.crad.2009.02.016","article-title":"Imaging of the gastrointestinal complications of systemic chemotherapy.","volume":"64","author":"Cronin","year":"2009","journal-title":"Clin Radiol"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.21037\/tcr-21-2501","article-title":"Immune checkpoint inhibitor-induced colitis complicated with inflammatory intestinal obstruction: a case report and literature review.","volume":"11","author":"Tan","year":"2022","journal-title":"Transl Cancer Res"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"15567","DOI":"10.1038\/s41598-020-72649-5","article-title":"Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3390\/curroncol29040200","article-title":"Immunotherapy in squamous cell cancer of the esophagus.","volume":"29","author":"Thuss-Patience","year":"2022","journal-title":"Curr Oncol"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17512433.2023.2274544","article-title":"Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials.","volume":"16","author":"Abushanab","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1245\/s10434-023-13383-w","article-title":"Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: the randomized phase II CISPD3 trial.","volume":"30","author":"Fu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"1210859","DOI":"10.3389\/fimmu.2024.1210859","article-title":"Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.","volume":"15","author":"Qiu","year":"2024","journal-title":"Front Immunol"},{"key":"R20-20260526","first-page":"ivad157","article-title":"Safety and efficacy of tislelizumab plus chemotherapy as preoperative treatment in potentially resectable locally advanced non-small-cell lung cancer patients.","volume":"38","author":"Huang","year":"2024","journal-title":"Interdiscip Cardiovasc Thorac Surg"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R22-20260526","first-page":"1","article-title":"Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.","volume":"4","author":"Wang","year":"2018","journal-title":"Chronic Dis Transl Med"},{"key":"R23-20260526","first-page":"4155","article-title":"Clinical analysis of intestinal obstruction after chemotherapy for gastrointestina malignant tumor.","volume":"42","author":"Xing","year":"2022","journal-title":"Chin J Gerontol"},{"key":"R24-20260526","first-page":"8089","article-title":"Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update.","volume":"29","author":"Davis","year":"2021","journal-title":"Support Care Cancer"},{"key":"R25-20260526","first-page":"4711","article-title":"MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer.","volume":"30","author":"Madariaga","year":"2022","journal-title":"Support Care Cancer"},{"key":"R26-20260526","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0041-1729922","article-title":"Malignant large bowel obstruction.","volume":"34","author":"Muldoon","year":"2021","journal-title":"Clin Colon Rectal Surg"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.2147\/IJWH.S366680","article-title":"Inoperable bowel obstruction in ovarian cancer: prevalence, impact and management challenges.","volume":"14","author":"Gonzalez-Ochoa","year":"2022","journal-title":"Int J Womens Health"},{"key":"R28-20260526","doi-asserted-by":"crossref","first-page":"e000437","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study.","volume":"8","author":"Shen","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R29-20260526","doi-asserted-by":"crossref","first-page":"257","DOI":"10.21147\/j.issn.1000-9604.2024.03.03","article-title":"Tislelizumab in previously treated, locally advanced unresectable\/metastatic microsatellite instability-high\/mismatch repair-deficient solid tumors.","volume":"36","author":"Li","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"R30-20260526","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial.","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol"},{"key":"R31-20260526","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R32-20260526","first-page":"4259","article-title":"Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors.","volume":"11","author":"Jiang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"R33-20260526","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"R34-20260526","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00262-022-03174-9","article-title":"Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.","volume":"71","author":"Jing","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:30:34Z","timestamp":1786048234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":34,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044910","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"2025-05-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}